RecruitingPhase 2NCT07071961
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Sponsor
M.D. Anderson Cancer Center
Enrollment
16 participants
Start Date
Feb 11, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Lorigerlimab and a drug called Regorafenib (CT) for people with colorectal, cancer, high risk patients, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRegorafenib (CT)
Given by po
DRUGLorigerlimab
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07071961
Related Trials
Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
NCT062719411 location
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT0752520635 locations
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT0600424538 locations
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT075785712 locations
Tislelizumab in People With Colorectal Cancer
NCT065295233 locations